Request a Quote/Business Development Products and Services Information Product Catalog Regulatory Status Supplying to Symbiotec News and Events Media Relations Website Feedback Others
Symbiotec Pharmalab Pvt. Limited (CIN: U24232MP2002PTC015293) Corporate office and Unit – I (Rau, Indore)
You say: “I admit I didn’t expect the stock to reach before ESMO, don’t expect it to move much higher without something new (Japan deal, phenomenal CABOSUN data, intriguing PD1 combo data or of course M&A)”
Yes, fair enough. However, there is a very high probability that a Japan deal will be announced soon OR that a Japanese company will acquire EXEL. Also, given what MammaRoche is doing you can safely expect intriguing PD1 combo data . Moreover CABOSUN data should indeed be very solid (or phenomenal).
No wonder that the stock is at 15$…
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.